scholarly journals Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Inki Lee ◽  
Byung Hyun Byun ◽  
Ilhan Lim ◽  
Byung Il Kim ◽  
Chang Woon Choi ◽  
...  
Keyword(s):  
Relative Risk ◽  
Neoadjuvant Chemotherapy ◽  
Clinical Outcome ◽  
Roc Curve ◽  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Early Response ◽  
Response Monitoring ◽  
Pet Ct ◽  
Extremity Osteosarcoma

Abstract Background To propose a personalized therapeutic approach in osteosarcoma treatment, we assessed whether sequential [18F]FDG PET/CT (PET/CT) could predict the outcome of patients with osteosarcoma of the extremities after one cycle and two cycles of neoadjuvant chemotherapy. Methods A total of 73 patients with AJCC stage II extremity osteosarcoma treated with 2 cycles of neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy were retrospectively analyzed in this study. All patients underwent PET/CT before (PET0), after 1 cycle (PET1), and after the completion of neoadjuvant chemotherapy (PET2), respectively. Maximum standardized uptake value (SUVmax) (corrected for body weight) and the % changes of SUVmax were calculated, and histological responses were evaluated after surgery. Receiver-operating characteristic (ROC) curve analyses and the Cox proportional hazards models were used to analyze whether imaging and clinicopathologic parameters could predict event-free survival (EFS). Results A total of 36 patients (49.3%) exhibited a poor histologic response and 17 patients (23.3%) showed events (metastasis in 15 and local recurrence in 2). SUVmax on PET2 (SUV2), the percentage change of SUVmax between PET0 and PET1 (Δ%SUV01), and between PET0 and PET2 (Δ%SUV02) most accurately predicted events using the ROC curve analysis. SUV2 (relative risk, 8.86; 95% CI, 2.25–34.93), Δ%SUV01 (relative risk, 5.97; 95% CI, 1.47–24.25), and Δ%SUV02 (relative risk, 6.00; 95% CI, 1.16–30.91) were independent predicting factors for EFS with multivariate analysis. Patients with SUV2 over 5.9 or Δ%SUV01 over − 39.8% or Δ%SUV02 over − 54.1% showed worse EFS rates than others (p < 0.05). Conclusions PET evaluation after 1 cycle of presurgical chemotherapy can predict the clinical outcome of extremity osteosarcoma. [18F]FDG PET, which shows a potential role in the early evaluation of the modification of timing of local control, can be a useful modality for early response monitoring of neoadjuvant chemotherapy.

Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential 18 F-FDG PET/CT and MRI

2014 ◽  
Vol 41 (8) ◽  
pp. 1553-1562 ◽  
Author(s):  
Byung Hyun Byun ◽  
Chang-Bae Kong ◽  
Ilhan Lim ◽  
Byung Il Kim ◽  
Chang Woon Choi ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Early Response ◽  
Response Monitoring ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Ct And Mri

Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?

2013 ◽  
Vol 39 (12) ◽  
pp. 1358-1363 ◽  
Author(s):  
W.P. Andrade ◽  
E.N.P. Lima ◽  
C.A.B.T. Osório ◽  
M. do Socorro Maciel ◽  
G. Baiocchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Early Response ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Response To Neoadjuvant Chemotherapy

Pretreatment 18F-FDG uptake heterogeneity predicts response to pyrotinib in patients with metastatic HER2-positive breast cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15026-e15026
Author(s):  
Cc Gong ◽  
Cheng Liu ◽  
Zhonghua Tao ◽  
Jian Zhang ◽  
Leiping Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Roc Curve ◽  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Curve Analysis ◽  
Roc Curve Analysis ◽  
Her2 Positive ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Positive Breast Cancer

e15026 Background: Heterogeneity of 18F-fluorodeoxyglucose (FDG) uptake is a promising marker for predicting response to treatment. This study aimed to evaluate the ability of pretreatment positron emission tomography/computed tomography (PET/CT) 18F-FDG-based heterogeneity to predict the response to pyrotinib in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Methods: Patients with MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FDG PET/CT before the initiation of pyrotinib was included. The intertumoral and intratumoral heterogeneity indexes (HI-inter and HI-intra, respectively), maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), and metabolic tumor volume (MTV) on the baseline PET/CT were assessed. Progression-free survival (PFS) was estimated by the Kaplan-Meier method and compared by log-rank test. Time-dependent receiver operating characteristic (ROC) curve analysis was performed, and the predictive accuracies of all markers were evaluated by plotting the cumulative area under the ROC curve (AUC) over time. Results: A total of 22 patients were included in this study. The median PFS of patients with a high HI-intra (> 1.9) was 6.6 months, whereas that of patients with a low HI-intra was 13.4 months (p = 0.044). The HI-inter was able to discriminate patients as well as the coefficient of variance. Univariate analysis showed that patients with a higher HI-inter tended to have worse PFS (10.6 months vs. 13.4 months, p = 0.067). Higher SUVmax and TLG were also associated with worse PFS. ROC curve analysis confirmed the predictive value of the HI-inter and HI-intra. TLG had the highest accuracy in predicting PFS (AUC = 0.87), followed by HI-inter (AUC = 0.86), SUVmax (AUC = 0.85), HI-intra (AUC = 0.80), mean standardized uptake value (AUC = 0.63), and MTV (AUC = 0.60). Conclusions: Intratumoral and intertumoral heterogeneities in metastatic lesions on pretreatment 18F-FDG PET/CT could predict response to pyrotinib treatment in patients with HER2-positive breast cancer, which could provide information to guide treatment decisions.

scholarly journals Utility of FDG-PET/CT in the Evaluation of the Response of Locally Advanced Breast Cancer to Neoadjuvant Chemotherapy

2014 ◽  
Vol 99 (4) ◽  
pp. 309-318 ◽  
Author(s):  
Kei Ogino ◽  
Masanobu Nakajima ◽  
Miyako Kakuta ◽  
Mitsuhiro Hayashi ◽  
Satoru Yamaguchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Reduction Rate ◽  
Standardized Uptake Value ◽  
Pet Ct ◽  
Significant Difference ◽  
Fdg Pet Ct

Abstract Neoadjuvant chemotherapy (NAC) is effective in down-staging a primary tumor before surgery, and quick differentiation between responders to NAC and nonresponders is needed. We investigated the utility of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) in evaluating the therapeutic effectiveness of NAC. We investigated 25 patients who underwent NAC for stage II and III noninflammatory breast cancer. FDG-PET/CT was undertaken before and after NAC to determine the maximum standardized uptake value (SUVmax) reduction rate. Findings were compared with postoperative histopathologic evaluation of therapeutic response. It was not possible to accurately assess tumor response to NAC using CT. However, using the SUVmax reduction rate, we noted a significant difference (P = 0.0420) between patients who were responsive and nonresponsive to NAC. The sensitivity and specificity were as high as 83.3% and 78.9%, respectively. This study demonstrated that FDG-PET/CT can differentiate responders from nonresponders. This improves patient management by avoiding unnecessary chemotherapy.

scholarly journals [18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Giulia Polverari ◽  
Francesco Ceci ◽  
Roberto Passera ◽  
Jacquelyn Crane ◽  
Lin Du ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Pediatric Patients ◽  
Early Response ◽  
Tissue Response ◽  
Secondary Outcome ◽  
Single Center ◽  
Pet Ct ◽  
Definitive Therapy ◽  
Fdg Pet Ct

Abstract Introduction This is a prospective, single-center trial in pediatric patients with sarcoma aiming to evaluate [18F]FDG PET/CT as a tool for early response assessment to neoadjuvant chemotherapy (neo-CTX). Methods Bone or soft tissue sarcoma patients with (1) baseline [18F]FDG PET/CT within 4 weeks prior to the start of neo-CTX (PET1), (2) early interim [18F]FDG PET/CT (6 weeks after the start of neo-CTX (PET2), (3) evaluation of neo-CTX response by histology or MRI, and (4) definitive therapy after neo-CTX (surgery or radiation) were included. Semiquantitative PET parameters (SUVmax, SUVmean, SUVpeak, MTV and TLG) and their changes from PET1 to PET2 (ΔPET) were obtained. The primary endpoint was to evaluate the predictive value of PET1, PET2 and ΔPET parameters for overall survival (OS) and time to progression (TTP). The secondary outcome was to evaluate if [18F]FDG PET/CT can predict the response to neo-CTX assessed by histopathology or MRI. Primary and secondary outcomes were also evaluated in a subpopulation of patients with bone involvement only. Results Thirty-four consecutive patients were enrolled (10 females; 24 males; median age 15.1 years). 17/34 patients (50%) had osteosarcoma, 13/34 (38%) Ewing's sarcoma, 2/34 (6%) synovial sarcoma and 2/34 (6%) embryonal liver sarcoma. Median follow-up was 39 months (range 16–84). Eight of 34 patients (24%) died, 9/34 (27%) were alive with disease, and 17/34 (50%) had no evidence of residual/recurrent disease. Fifteen of 34 (44%) and 19/34 (56%) were responders and non-responders, respectively. PET2-parameters were associated with longer TTP (p < 0.02). ΔMTV was associated with tissue response to neo-CTX (p = 0.047). None of the PET1, PET2 or ΔPET parameters were associated with OS. Conclusion [18F]FDG PET/CT performed 6 weeks after the start of neo-CTX can serve as an early interim biomarker for TTP and pathologic response but not for OS in pediatric patients with sarcoma.

139. Relevance of breast cancer subtypes in response monitoring with 18F-FDG PET/CT during neoadjuvant chemotherapy

2012 ◽  
Vol 38 (9) ◽  
pp. 777-778
Author(s):  
B.B. Koolen ◽  
K.E. Pengel ◽  
J. Wesseling ◽  
W.V. Vogel ◽  
M. Vrancken Peeters ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Breast Cancer Subtypes ◽  
Response Monitoring ◽  
Cancer Subtypes ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Combined use of 18F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy

2014 ◽  
Vol 41 (8) ◽  
pp. 1515-1524 ◽  
Author(s):  
Kenneth E. Pengel ◽  
Bas B. Koolen ◽  
Claudette E. Loo ◽  
Wouter V. Vogel ◽  
Jelle Wesseling ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Response Monitoring ◽  
Combined Use ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Ct And Mri
Sign in / Sign up

Export Citation Format

Share Document